0001104659-15-011169.txt : 20150218 0001104659-15-011169.hdr.sgml : 20150216 20150217143426 ACCESSION NUMBER: 0001104659-15-011169 CONFORMED SUBMISSION TYPE: SC 13G PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20150217 DATE AS OF CHANGE: 20150217 GROUP MEMBERS: MICHEL PAIRET GROUP MEMBERS: THEO NIEUWENHUIS SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: Vitae Pharmaceuticals, Inc CENTRAL INDEX KEY: 0001157602 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G SEC ACT: 1934 Act SEC FILE NUMBER: 005-88337 FILM NUMBER: 15621104 BUSINESS ADDRESS: STREET 1: 502 WEST OFFICE CENTER DR CITY: FORT WASHINGTON STATE: PA ZIP: 19034 BUSINESS PHONE: 215-461-2000 MAIL ADDRESS: STREET 1: 502 WEST OFFICE CENTER DR CITY: FORT WASHINGTON STATE: PA ZIP: 19034 FORMER COMPANY: FORMER CONFORMED NAME: Vitae Pharmaceuticals Inc DATE OF NAME CHANGE: 20050118 FORMER COMPANY: FORMER CONFORMED NAME: CONCURRENT PHARMACEUTICALS INC DATE OF NAME CHANGE: 20010815 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: Boehringer Ingelheim R&D Beteiligungs GmbH CENTRAL INDEX KEY: 0001634111 IRS NUMBER: 000000000 STATE OF INCORPORATION: 2M FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G BUSINESS ADDRESS: STREET 1: BINGER STRASSE 173 CITY: INGELHEIM STATE: 2M ZIP: 55216 BUSINESS PHONE: 0049-6132-7790954 MAIL ADDRESS: STREET 1: BINGER STRASSE 173 CITY: INGELHEIM STATE: 2M ZIP: 55216 SC 13G 1 a15-4606_1sc13g.htm SC 13G

 

CUSIP No. 92847N103

13G

 

 

 

UNITED STATES

 

 

SECURITIES AND EXCHANGE COMMISSION

 

 

Washington, D.C. 20549

 

 

 

 

 

SCHEDULE 13G

(Rule 13d-102)

 

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED

PURSUANT TO RULE 13d-2

(Amendment No.     )*

 

Vitae Pharmaceuticals, Inc.

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

92847N103

(CUSIP Number)

December 31, 2014

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

o

Rule 13d-1(b)

o

Rule 13d-1(c)

x

Rule 13d-1(d)

 

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

 

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 


 

CUSIP No. 92847N103

13G

 

 

 

1.

Names of Reporting Persons
Boehringer Ingelheim R&D Beteiligungs GmbH

 

 

2.

Check the Appropriate Box if a Member of a Group

 

 

(a)

o

 

 

(b)

o

 

 

3.

SEC Use Only

 

 

4.

Citizenship or Place of Organization
Germany

 

 

 

Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With

5.

Sole Voting Power
None

 

6.

Shared Voting Power
1,086,956

 

7.

Sole Dispositive Power
None

 

8.

Shared Dispositive Power
1,086,956

 

 

9.

Aggregate Amount Beneficially Owned by Each Reporting Person
1,086,956

 

 

10.

Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares   o

 

 

11.

Percent of Class Represented by Amount in Row 9
5.9% (1)

 

 

12.

Type of Reporting Person
CO

 

(1)   Based on 18,418,196 shares of Common Stock outstanding as of December 31, 2014, per the Vitae Pharmaceuticals, Inc. Form S-1 (File No. 333-201389).

 

2


 

CUSIP No. 92847N103

13G

 

 

 

1.

Names of Reporting Persons
Theo Nieuwenhuis

 

 

2.

Check the Appropriate Box if a Member of a Group

 

 

(a)

o

 

 

(b)

o

 

 

3.

SEC Use Only

 

 

4.

Citizenship or Place of Organization
The Netherlands

 

 

 

Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With

5.

Sole Voting Power
None

 

6.

Shared Voting Power
1,086,956

 

7.

Sole Dispositive Power
None

 

8.

Shared Dispositive Power
1,086,956

 

 

9.

Aggregate Amount Beneficially Owned by Each Reporting Person
1,086,956

 

 

10.

Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares   o

 

 

11.

Percent of Class Represented by Amount in Row 9
5.9% (1)

 

 

12.

Type of Reporting Person
IN

 

(1)   Based on 18,418,196 shares of Common Stock outstanding as of December 31, 2014, per the Vitae Pharmaceuticals, Inc. Form S-1 (File No. 333-201389).

 

3


 

CUSIP No. 92847N103

13G

 

 

 

1.

Names of Reporting Persons
Michel Pairet

 

 

2.

Check the Appropriate Box if a Member of a Group

 

 

(a)

o

 

 

(b)

o

 

 

3.

SEC Use Only

 

 

4.

Citizenship or Place of Organization
France

 

 

 

Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With

5.

Sole Voting Power
None

 

6.

Shared Voting Power
1,086,956

 

7.

Sole Dispositive Power
None

 

8.

Shared Dispositive Power
1,086,956

 

 

9.

Aggregate Amount Beneficially Owned by Each Reporting Person
1,086,956

 

 

10.

Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares   o

 

 

11.

Percent of Class Represented by Amount in Row 9
5.9% (1)

 

 

12.

Type of Reporting Person
IN

 

(1)   Based on 18,418,196 shares of Common Stock outstanding as of December 31, 2014, per the Vitae Pharmaceuticals, Inc. Form S-1 (File No. 333-201389).

 

4


 

CUSIP No. 92847N103

13G

 

 

Item 1 (a).

Name of Issuer:

 

Vitae Pharmaceuticals, Inc.

Item 1 (b).

Address of Issuer’s Principal Executive Offices:

 

502 West Office Center Drive

Fort Washington, PA 19034

 

Item 2 (a).

Name of Person Filing:

Item 2 (b).

Address of Principal Business Office or, if none, Residence:

Item 2 (c).

Citizenship:

 

Boehringer Ingelheim R&D Beteiligungs GmbH

Binger Strasse 173

55216 Ingelheim am Rhein

Germany

Citizenship: Germany

 

Theo Nieuwenhuis

c/o Boehringer Ingelheim R&D Beteiligungs GmbH

Binger Strasse 173

55216 Ingelheim am Rhein

Germany

Citizenship: The Netherlands

 

Michel Pairet

c/o Boehringer Ingelheim R&D Beteiligungs GmbH

Binger Strasse 173

55216 Ingelheim am Rhein

Germany

Citizenship: France

 

 

Each of the foregoing is referred to as a “Reporting Person” and collectively as the “Reporting Persons.”

 

 

Item 2 (d).

Title of Class of Securities:

 

Common Stock, par value $0.0001 per share

Item 2 (e).

CUSIP Number:

 

92847N103

 

5


 

CUSIP No. 92847N103

13G

 

 

Item 3.

If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:

 

 

 

Not Applicable

 

 

Item 4.

Ownership:

 

 

Theo Nieuwenhuis and Dr. Michel Pairet are the Managing Directors of Boehringer Ingelheim R&D Beteiligungs GmbH (“BI R&D”) and may be deemed to have shared voting and dispositive power over the shares owned by BI R&D. Such persons disclaim beneficial ownership over the shares owned by BI R&D except to the extent of any pecuniary interest therein.

 

 

 

 

The information below is with respect to each Reporting Person:

 

 

 

(a)

Amount beneficially owned:   

 

1,086,956

 

(b)

Percent of class:   

 

5.9%

 

 

 

 

(c)

Number of shares as to which such person has:

 

 

 

 

 

(i)

Sole power to vote or to direct the vote     

None

 

 

 

 

(ii)

Shared power to vote or to direct the vote    

1,086,956

 

 

 

 

(iii)

Sole power to dispose or to direct the disposition of   

None

 

 

 

 

(iv)

Shared power to dispose or to direct the disposition of   

1,086,956

 

6


 

CUSIP No. 92847N103

13G

 

 

Item 5.

Ownership of Five Percent or Less of a Class:

 

 

If this Statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following [X].

 

In January 2015, Vitae Pharmaceuticals, Inc. issued an additional 3,450,000 shares of Common Sock in a public offering (File No. 333-201389), and the Reporting Persons are no longer the beneficial owners of more than 5% of the Common Stock as of the date hereof.

 

Item 6.

Ownership of More than Five Percent on Behalf of Another Person:

 

 

 

Not Applicable

 

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person:

 

 

 

Not Applicable

 

Item 8.

Identification and Classification of Members of the Group:

 

 

 

Not Applicable.  The Reporting Persons expressly disclaim membership in a “group” as used in Rule 13d-5(b)(1).

 

Item 9.

Notice of Dissolution of Group:

 

 

 

Not Applicable

 

Item 10.

Certifications:

 

 

 

Not Applicable

 

7


 

CUSIP No. 92847N103

13G

 

 

Signature

 

After reasonable inquiry and to the best of his or its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

 

Dated:  February 16, 2015

 

 

 

BOEHRINGER INGELHEIM R&D BETEILIGUNGS GMBH

 

 

 

/s/ Theo Nieuwenhuis

 

Name: Theo Nieuwenhuis

 

Title: Managing Director

 

 

 

/s/ Michel Pairet

 

Name: Michel Pairet

 

Title: Managing Director

 

 

 

/s/ Theo Nieuwenhuis

 

Theo Nieuwenhuis

 

 

 

/s/ Michel Pairet

 

Michel Pairet

 

 

8


 

Exhibit 1

 

Joint Filing Agreement

 

Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, each of the undersigned hereby agrees that only one statement containing the information required by Schedule 13G need be filed with respect to the ownership by each of the undersigned of shares of common stock of Vitae Pharmaceuticals, Inc.  This Agreement may be executed in any number of counterparts, each of which shall be deemed an original.

 

Dated:  February 16, 2015

 

 

 

 

 

BOEHRINGER INGELHEIM R&D BETEILIGUNGS GMBH

 

 

 

 

 

/s/ Theo Nieuwenhuis

 

Name: Theo Nieuwenhuis

 

Title: Managing Director

 

 

 

 

 

/s/ Michel Pairet

 

Name: Michel Pairet

 

Title: Managing Director

 

 

 

 

 

/s/ Theo Nieuwenhuis

 

Theo Nieuwenhuis

 

 

 

 

 

/s/ Michel Pairet

 

Michel Pairet